CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 23, 2011
Result type: Reports
Project Number: S0244
Product Line: Common Drug Review

Generic Name: Linagliptin

Brand Name: Trajenta

Manufacturer: Boehringer Ingelheim Canada

Indications: Diabetes mellitus, Type 2

Submission Type: New

Project Status: Complete

Date Recommendation Issued: February 15, 2012

Recommendation Type: List with clinical criteria and/or conditions